跳至主要内容
临床试验/IRCT20200128046294N2
IRCT20200128046294N2已完成3 期

A prospective randomized controlled trial comparing Sovodak (Sofosbuvir plus Daclatasvir) in participants with moderate to severe Coronavirus disease (COVID-19) compared to standard of care treatment

Digestive Disease Research Institute0 个研究点目标入组 70 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Both genders
  • Age =18 years at time of signing Informed Consent Form
  • Willing and able to provide written informed consent prior to performing study to any assigned treatment arm
  • Must agree not to enroll in another study of an investigational agent prior to completion of study
  • Will be admitted to Shariati hospital (Tehran), Baharloo (Tehran), Sina (Tehran), Sayyad Shirazi (Gorgan) and not transferred to another hospital
  • Laboratory (RT-PCR) confirmed infection with 2019-nCoV
  • Lung involvement confirmed with chest CT scan
  • Hospitalized patients with: Fever (Oral temperature = 37.8 ?) and at least one of Respiratory rate >24/min / O2Sat<94% or the Pa02/Fi02 ratio <300mgHg
  • =8 days since illness onset

排除标准

  • Known allergic reaction to Sofosbuvir or Daclatasvir
  • Pregnant or breastfeeding, or positive pregnancy test
  • Receipt of any experimental treatment for COVID-19 prior to the time of the screening evaluation
  • Heart rate < 60/min
  • Taking Amiodarone
  • Evidence of multiorgan failure
  • Requiring mechanical ventilation at screening
  • eGFR< 50 mL/min

研究者

相似试验